Sylentis S.A.U.
https://www.sylentis.com/index.php/en/
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Sylentis S.A.U.
OKYO Hits Multiple Dry Eye Endpoints, Plans Move Into Phase III
OKYO’s eye drop OK-101 has hit endpoints for ocular pain, tear film breakup time and conjunctival staining in Phase II, while demonstrating a placebo-like tolerability profile.
Sylentis Piles On Another Failure In Dry Eye
The PharmaMar subsidiary is the latest group to crash in a notoriously hard-to-treat disease, leaving Bausch + Lomb more firmly in command of the field.
HanAll Advancing Novel Dry Eye Contender Despite Mixed Top-Line
HanAll and Daewoong remain upbeat on dry eye candidate HL036 and are gearing up for a second Phase III US study despite the first missing its primary endpoint in just-released top-line results.
Mixed Results From ReGenTree's DES Therapy In Second Phase III
ReGenTree has reported mixed results in its second pivotal Phase III trial of RGN-259 indicating that the therapy is most effective in patients with severe dry eye. The results raise some doubts about the treatment’s potential approval for the general dry eye population.
Company Information
- Industry
- Biotechnology
- Pharmaceuticals
-
Biotechnology
- Gene Therapy, Cell Therapy
-
Drug Discovery Tools
- Genomics-Proteomics
- Other Names / Subsidiaries
-
- Zeltia S.A.
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice